好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Single-Center Experience with Local Field Potential-Guided Initial Deep Brain Stimulation Programming in Parkinson’s Disease
Movement Disorders
P4 - Poster Session 4 (8:00 AM-9:00 AM)
5-005

To describe the use of local field potentials (LFP) as an objective measure to guide initial deep brain stimulation (DBS) programming in Parkinson disease (PD).

Fluctuations in beta frequency LFP power (13-30Hz) are a biomarker of motor symptom control in PD, suppressible by levodopa and stimulation in correlation with symptom improvement. The localization of the highest beta signal often correlates with the location of the most effective stimulating contact.   There is opportunity to use beta LFPs in DBS programming optimization.

We conducted a retrospective chart review of PD patients who underwent initial OFF-medication programming using the Medtronic Percept™ platform. The strongest beta LFP peak was identified using the Brainsense™ survey along with the frequency band of interest for chronic sensing. LFP suppression and clinical response were observed while titrating the stimulation at the contact with the highest beta power. Stimulation and sensing parameters were observed over a 6-month period. Stimulation efficacy was measured using the MDS-UPDRS3 score and the levodopa equivalent daily dose (LEDD).

Amongst eight patients with 15 leads (9-STN, 4-GPi), n=12 leads had measurable beta peaks with mean frequency=17.50Hz (range 7.81-27.34) and mean power=2.89uVp (range 1.15-6.64). With chronic sensing at mean frequency=18.31Hz +/-2.5Hz (range 11.72-28.32), n=12 leads showed beta suppression with stimulation titration and symptom improvement. Stimulation-limiting side effects were seen in n=7 and all resolved by the second session. Traditional monopolar review was required in one lead. The stimulating contact was changed in n=10 (seven to double monopolar), and the sensed band in n=12, due to a shifting beta peak, all by the third visit. Mean MDS-UPDRS3 improvement at 6mos was 51% (range 22%-82%), and LEDD reduction was 30% (range -13%-100%).

LFP-guided initial programming facilitates effective contact selection and troubleshooting during stimulation optimization. Long term outcomes and comparison to other programming techniques are needed.

Authors/Disclosures
Osama M. Abu-hadid, MD
PRESENTER
Dr. Abu-hadid has nothing to disclose.
Joohi Jimenez Shahed, MD, FAAN (Icahn School of Medicine at Mount Sinai) Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Teva. Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medtronic. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Jimenez Shahed has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for BlueRock. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Treefrog. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Consultant for RebrAIn. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BlueRock Therapeutics. Dr. Jimenez Shahed has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PhotoPharmics. Dr. Jimenez Shahed has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Emalex. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. The institution of Dr. Jimenez Shahed has received research support from Amneal. The institution of Dr. Jimenez Shahed has received research support from Annovis. The institution of Dr. Jimenez Shahed has received research support from SAGE. The institution of Dr. Jimenez Shahed has received research support from Ono Pharmaceuticals. The institution of Dr. Jimenez Shahed has received research support from BlueRock. The institution of Dr. Jimenez Shahed has received research support from Neuron23. Dr. Jimenez Shahed has received personal compensation in the range of $0-$499 for serving as a Faculty with Movement Disorders Society. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Faculty with 好色先生. Dr. Jimenez Shahed has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with Parkinson Foundation.